Open Slide Modal

Inside Ensoma

Ensoma /enˈsōmə/ is derived from the Greek phrase “en soma,” meaning in vivo or in the body.

About Us

Ensoma believes the future of medicine lies within us. 

We have a bigger, bolder vision for gene therapy: Treatments as versatile, precise and far-reaching as the body’s own cells. One therapy, one cure – with minimal or no added burden for patients.

And we have the breakthrough to deliver this vision: Engenious™ is the first gene therapy platform to precisely engineer any or all hematopoietic and immune cells with a one-time, off-the-shelf in vivo treatment. We’ve already broken through the limitations of today’s approaches – now we’re focused on a limitless future. 

For the first time, providing the power of gene therapy to every person in need is within reach. For our team, realizing this vision is personal. Founded and guided by leaders drawn from the top of the cell and gene therapy field, we feel an urgency and passion for our work driven by its potential global impact.

Group Image
Group Image
Group Image
Group Image


We have empowered each of our team members to make decisions, overcome obstacles, take risks and — ultimately — achieve what hasn’t been done before.

Emile Nuwaysir, Ph.D.

President, Chief Executive Officer and Board Member

Robert Peters,

Chief Scientific Officer

Daniel Leblanc

Chief Technology Officer

Naina Bhasin,

Chief Business Officer

Patrick Au,

Vice president, Translational Research and Early Development

John DeSimone

Vice President, Finance

Anthony Forget,

Vice President, Platform technology

Joe Salas, Ph.D.

Vice president, biology

Soumitra Roy,
M.D., Ph.D.

Distinguished investigator

Betsy Bogard

Head of Program and Alliance Management

Dawn Houlihan

Head of Quality

Chapman Wright,

Head of Process and Analytical Development


Hans-Peter Kiem, M.D., Ph.D.

Chief Scientific and Clinical Advisor, Ensoma
Fred Hutchinson Cancer Research Center & University of Washington

André Lieber, M.D., Ph.D.

University of Washington

Board of Directors

Paula Soteropoulos

Chairman; Strategic Advisor 5AM Ventures

Albert Seymour,

Chief Scientific Officer, Homology Medicines

Kush M. Parmar,
M.D., Ph.D.

Founding CEO; Managing Partner, 5AM Ventures

Stephen Knight,

President and Managing Partner, F-Prime CAPTIAL

Emile Nuwaysir, Ph.D.

President, Chief Executive Officer and Board Member

Scientific Advisory Board

Hans-Peter Kiem,
M.D., Ph.D.

Chair; Fred Hutchinson Cancer Research Center & University of Washington

Anja Ehrhardt,

Universität Witten/Herdecke

Crystal Mackall, M.D.

The Stanford University School of Medicine

Harry Malech, M.D.

National Institute of Allergy and Infectious Diseases, National Institutes of Health

Vijay Sankaran,
M.D., Ph.D.

Boston Children’s Hospital

Mark Walters,

University of California San Francisco



At Ensoma, we are dedicated to making an impact for patients around the world. Join us in our mission.